K36 Therapeutics
- Headquarters
- New York, New York
- Employees
- 1–10
- Founded
- 2021
- Business Model
- B2B
- Website
- k36tx.com
- Total Funding
- $100.0M
- Last Round
- $70.0M Series BJun 2023
About
Clinical-stage biotech developing selective oral NSD2/MMSET inhibitors for multiple myeloma and prostate cancer patients.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account